Zobrazeno 1 - 10
of 158
pro vyhledávání: '"I Warrier"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
S. Miller, J.J. Hutter, H.A. Cooper, I. Warrier, M.L. Schmidt, N.L. Seibel, Steven Arkin, A. Shapiro
Publikováno v:
Pathophysiology of Haemostasis and Thrombosis. 28:93-98
Activated recombinant human coagulation factor VII (rFVIIa) is a promising new therapeutic agent for patients with hemophilia A or B with inhibitors who experience serious bleeding episodes or who need coverage during surgical procedures. This open-l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cfe9a3e56a45e4088b1948fb978fa7e5
https://doi.org/10.1159/000022418
https://doi.org/10.1159/000022418
Autor:
JN George, SH Woolf, GE Raskob, JS Wasser, LM Aledort, PJ Ballem, VS Blanchette, JB Bussel, DB Cines, JG Kelton, AE Lichtin, R McMillan, JA Okerbloom, DH Regan, I Warrier
Publikováno v:
Blood. 88:3-40
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b681add3c55aae2529fcac0eba22728
https://doi.org/10.1182/blood.v88.1.3.3
https://doi.org/10.1182/blood.v88.1.3.3
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 17(3)
Inhibitor development continues to be a major problem in the treatment of haemophilia. Immune tolerance induction (ITI) continues to be the most effective approach to managing this complication. This study reviews the practice and outcome of ITI at a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a361b0917b9e892b78b85473ddc86ef0
https://pubmed.ncbi.nlm.nih.gov/21118335
https://pubmed.ncbi.nlm.nih.gov/21118335
Autor:
V S, Blanchette, A D, Shapiro, R J, Liesner, F, Hernández Navarro, I, Warrier, P C, Schroth, G, Spotts, B M, Ewenstein, P, Collins
Publikováno v:
Journal of thrombosis and haemostasis : JTH. 6(8)
Summary. Background: The pharmacokinetics of factor VIII replacement therapy in preschool previously treated patients (PTPs) with hemophilia A have not been well characterized. Objectives: To assess the pharmacokinetics, efficacy and safety of a plas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::206bd8159504ecbc4ecfb95fb093fcd0
https://pubmed.ncbi.nlm.nih.gov/18503631
https://pubmed.ncbi.nlm.nih.gov/18503631
Autor:
I. Warrier
Publikováno v:
Inhibitors in Patients with Haemophilia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa5bdbef7a2e4f8948c379ffb99c30a1
https://doi.org/10.1002/9780470757260.ch14
https://doi.org/10.1002/9780470757260.ch14
Publikováno v:
Haemophilia. 4:574-576
The development of inhibitor antibodies is a serious complication of haemophilia in young children. Occurrence of anaphylaxis at the time of inhibitor development is a recently described complication unique to haemophilia B. Management of these inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb661b95f5ac3f93034d3d62ed187794
https://doi.org/10.1046/j.1365-2516.1998.440574.x
https://doi.org/10.1046/j.1365-2516.1998.440574.x
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 9(3)
The aim of this retrospective review was to assess the overall effectiveness of prophylaxis when compared with on-demand treatment of haemophilic patients. Twenty-five children (22 with severe haemophilia A and three with severe haemophilia B) were e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::55857c5e4b406eb971d1e30fab8852d8
https://pubmed.ncbi.nlm.nih.gov/12694517
https://pubmed.ncbi.nlm.nih.gov/12694517
Autor:
I, Warrier
Publikováno v:
Haematologica. 85
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::400d4d921ac275bc66efe92470af7c5a
https://pubmed.ncbi.nlm.nih.gov/11187867
https://pubmed.ncbi.nlm.nih.gov/11187867
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 6(3)
The development of an inhibitor to transfused factor VIII (FVIII) is a serious treatment-related problem in haemophiliac children. The management of patients with high titre FVIII inhibitors is difficult, and immune tolerance induction (ITI) is the o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::70094dd3c499671b67adf4e682ade5d2
https://pubmed.ncbi.nlm.nih.gov/10792472
https://pubmed.ncbi.nlm.nih.gov/10792472